Researcher:
Baydar, Dilek Ertoy

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Dilek Ertoy

Last Name

Baydar

Name

Name Variants

Baydar, Dilek Ertoy

Email Address

Birth Date

Filters

2018 - 201952020 - 202319

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.b64e1478-1296-4400-a64d-08bbe3acdbb8

Search Results

Now showing 1 - 10 of 26
  • Placeholder
    PublicationMetadata only
    Fluorescence-guided extended pelvic lymphadenectomy during robotic radical prostatectomy
    (Springernature) N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Özkan, Arif; Köseoğlu, Ersin; Canda, Abdullah Erdem; Çil, Barbaros Erhan; Aykanat, İbrahim Can; Sarıkaya, Ahmet Furkan; Tarım, Kayhan; Armutlu, Ayşe; Kulaç, İbrahim; Barçın, Erinç; Falay, Fikri Okan; Kordan, Yakup; Baydar, Dilek Ertoy; Balbay, Mevlana Derya; Esen, Tarık; Doctor; Faculty Member; Faculty Member; Faculty Member; Doctor; Researcher; Researcher; Teaching Faculty; Faculty Member; Undergraduate Student; Teaching Faculty; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; N/A; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 350876; 116202; 169993; N/A; 327615; 327605; 133567; 170305; N/A; 246484; 157552; 8025; 153320; 50536
    We evaluated and described the impact of prostatic indocyanine green (ICG) injection on extended pelvic lymph node (LN) dissection (ePLND) in robotic-assisted radical prostatectomy (RARP). Between January 2019 and December 2021, we included consecutive 50 PCa patients who underwent ePLND during RARP with (n = 25) or without (n = 25) prostatic ICG injection. ICG injection was performed during abdominal port placement and robot docking. Pelvic LNs reflecting green color were initially excised and then the template was completed. The outcomes of two groups were compared. Overall, nine (36%) and five (20%) of the patients had metastatic LN involvement in the ICG and non-ICG groups, respectively. Of the 509 dissected LNs in the ICG group, 122 (23.9%) were fluorescence active. 20 LNs (3.9%) were metastatic in this group, 9 (45%) of which were ICG+. 408 LNs were resected on the non-ICG group with 8(1.9%) being metastatic. Eight (88.9%) of nine pN+ patients were florescent positive in the ICG group. Out of six patients with pN+ disease, Ga68 PSMA-PET/CT detected positive LNs preoperatively. In addition to preoperative Ga68 PSMA-PET/CT investigation, ICG-guided ePLND might increase identification and removal of metastatic LNs duirng RARP. Improvements in staging and oncologic outcomes may also be seen in intermediate- and high-risk patients.
  • Placeholder
    PublicationMetadata only
    The role of TC-99M MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?
    (Elsevier, 2020) Asi, Tariq; Tuncali, Meltem Caglar; Tuncel, Murat; Alkanat, Nazli Eylem Imamoglu; Hazir, Berk; Kosemehmetoglu, Kemal; Akdogan, Bulent; N/A; Baydar, Dilek Ertoy; Faculty Member; School of Medicine; 8025
    Introduction: Despite the increasing accuracy of imaging modalities, the rate of benign renal tumors misclassified as malignant before surgery still non-negligible. Tc-99m sestamibi was demonstrated to be a possible reliable agent in discriminating oncocytoma from renal cell carcinoma (RCC). We aimed to study the efficacy of Tc-99m MIBI tumor scintigraphy in evaluating clinical T1 renal masses. Methods and Materials: Between July 2017 and March 2019, patients with clinical T1 renal mass underwent preoperative Tc-99m sestamibi tumor scintigraphy. Tc-99m sestamibi tumor scintigraphy findings were correlated with the postoperative pathology results. Results: A total of 90 renal masses were included in the study. Male to female ratio was 67/23. The mean age and tumor size were 55.5 +/- 11.4 years and 4 +/- 1.4 cm, respectively. In pathological evaluation, 20% (18/90) of masses were reported as benign (10 oncocytomas, 4 angiomyolipomas (AML), 2 chronic sclerosis, 1 fibroma and 1 hydatid cyst). While Tc-99m sestamibi uptake was positive in all oncocytomas; 6 patients with chronic sclerosis, fibroma, hydatid cyst and angiomyoli-poma pathologies had no uptake. Except for 5 chromophobe cell RCC and 3 oncocytic papillary RCC masses, malignant lesions had no uptake. In predicting benign pathology, Tc-99m sestamibi tumor scintigraphy had positive and negative predictive value of 60% and 91.3%, respectively. The mean Tc-99m 2-methoxy isobutyl isonitrile lesion/normal renal parenchyma ratio of benign and malignant lesions was 0.6 and 0.37, respectively. A relative uptake of 0.49 was an acceptable cutoff point to discriminate oncocytomas from all other pathologies. Conclusion: Tc-99m sestamibi tumor scintigraphy has a beneficial role in the assessment of clinical T1 renal mass. Masses with negative uptake harbor high probability of being malignant. While evaluating masses with positive uptake, it should be kept in mind that some malignant pathologies may demonstrate similar results. (C) 2020 Elsevier Inc. All rights reserved.
  • Placeholder
    PublicationMetadata only
    Post-transplant recurrence of masked monoclonal gammopathy of renal significance in a patient with C3 glomerulonephritis: a case report
    (Lippincott Williams & Wilkins, 2022) N/A; N/A; N/A; N/A; N/A; N/A; N/A; Yelken, Berna; Arpalı, Emre; Akyollu, Başak; Koçak, Burak; Baydar, Dilek Ertoy; Akay, Olga Meltem; Türkmen, Aydın; Doctor; Doctor; Doctor; Faculty Member; Faculty Member; Faculty Member; Doctor; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine, School of Medicine; N/A; N/A; N/A; N/A; 8025; 170966; N/A
    Introduction: Monoclonal gammopathy of renal significance (MGRS) is a recently defined group of renal diseases caused by monoclonal immunoglobulin secreted by nonmalignant proliferative B cell or plasma cell causes renal damage. Here we report a case known as primary kidney disease C3 glomerulonephritis but after kidney transplant diagnosed MGRS. Case presentation: A 32-year old man underwent live related renal transplant in December 2020 for ESRF secondary C3 glomerulonephritis. At 2 months post-transplant, his serum kreatinin levels increased from a basaline creatinine of 1.2 mg/dl to 1.7mg/dl, and he developed proteinuria (1.2 gr/day). Renal biopsy showed monoclonal membranoproliferative glomerulonephritis. His serum and urine kappa/lambda light chain ratio was normal and he had no monoclonal protein in serum and urine immunfixation electrophoresis. After the patient was treated with Rituximab (4 cycles), his serum creatinin levels and proteinuria increased and repeat biopsy showed increase of monoclonal immun complexes in glomeruler capillers. The patient was treated bortezomib-based chemotherapy (4 cycles). Repeat biopsy showed no regression renal pathology. His renal functions and proteinuria continued to deteriorate. There were a rise in urine kappa/lambda light chain ratio. He received no further chemotherapy, a decision was taken to manage her kidney condition conservatively. Conclusions: Monoclonol immunoglobulin deposits may not be detectable in standart immunofluorescence techniques and can result missing the diagnosis of MGRS. Patiens with C3glomerulonephritis should be examined in detail for monoclonal gammapathy before kidney transplantation. 
  • Placeholder
    PublicationMetadata only
    How closely related are juxtaglomerular cell tumors to other pericytic tumors, molecularly?
    (SPRINGERNATURE, 2022) Canete-Portillo, Sofia; McKenney, Jesse; Pan, Chin-Chen; Aron, Manju; Wilk, Brandon; Massicano, Felipe; Gajapathy, Manavalan; Brown, Donna; Matoso, Andres; Pena, Maria Del Carmen Rodriguez; Tretiakova, Maria; Trpkov, Kiril; Williamson, Sean; Mackinnon, Alexander; Harada, Shuko; Worthey, Elizabeth; Magi-Galluzzi, Cristina; N/A; Baydar, Dilek Ertoy; Faculty Member; N/A; School of Medicine; N/A; 8025
  • Placeholder
    PublicationMetadata only
    Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy
    (Springer, 2020) Aydin, Ahmet Murat; Hazir, Berk; Babaoglu, Berrin; Bilen, Cenk Y.; N/A; Baydar, Dilek Ertoy; Faculty Member; School of Medicine; 8025
    Purpose Programmed cell death-1 ligand-1 (PD-L1) expression has been associated with prognostic implications in urologic malignancies. We aimed to investigate prognostic significance of pre- and post-treatment PD-L1 expression in patients treated with BCG for high-grade non-muscle-invasive bladder cancer (NMIBC). Methods We reviewed a total of 141 high-grade NMIBC cases treated with transurethral resection + >= 6 BCG instillations between 2004 and 2017. PD-L1 immunohistochemistry (IHC) scoring was done on 0-3 scale, and cut-off for positive and high-level PD-L1 expression was set to >= 1% and >= 5% staining of tumor-infiltrating immune cells (IC), respectively. Clinicopathologic characteristics and oncologic outcomes [recurrence-free (RFS) and progression-free survival (PFS)] were compared, stratified by PD-L1 positivity. The prognostic role of PD-L1 was assessed using Kaplan-Meier, and univariate and multivariate Cox regression analyses. Results Pre-treatment, 46.2% and 6.8% of high-grade NMIBC demonstrated positive and high-level PD-L1 expression, respectively. Positive PD-L1 expression was associated with submucosal invasion and refractory-tumor recurrence. PD-L1 expression was not associated with RFS or PFS in regression analysis. Post-treatment, 55.1% and 11.6% of recurrent tumors demonstrated positive and high-level PD-L1 expression, respectively. Down-regulation of PD-L1 expression was noted in patients with refractory recurrence (p = 0.012). Conclusion Pre-treatment PD-L1 expression was associated with unfavorable pathological features in primary high-grade NMIBC and its expression level after BCG immunotherapy was significantly decreased in patients with refractory recurrence. PD-L1 expression did not have prognostic value for PFS or RFS; therefore, further research is necessary to identify novel biomarkers for prediction of disease outcomes in high-grade NMIBC.
  • Placeholder
    PublicationMetadata only
    A difficult diagnosis in a child with renal mass: desmoplastic small round cell tumour of the kidney
    (Springer, 2018) Aydin, Özkan; N/A; N/A; Armutlu, Ayşe; Baydar, Dilek Ertoy; Teaching Faculty; Faculty Member; School of Medicine; School of Medicine; 133567; 8025
    N/A
  • Placeholder
    PublicationMetadata only
    Molecular characterization of juxtaglomerular cell tumors
    (Springer, 2022) Canete-Portillo, Sofia; McKenney, Jesse; Aron, Manju; Wilk, Brandon; Massicano, Felipe; Gajapathy, Manavalan; Brown, Donna; Baydar, Dilek; Matoso, Andres; Pena, Maria Del Carmen Rodriguez; Pan, Chin-Chen; Tretiakova, Maria; Rais-Bahrami, Soroush; Mackinnon, Alexander; Harada, Shuko; Worthey, Elizabeth; Magi-Galluzzi, Cristina; N/A; Baydar, Dilek Ertoy; Faculty Member; N/A; School of Medicine; N/A; 8025
  • Placeholder
    PublicationMetadata only
    Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations
    (Elsevier, 2019) Palsgrove, Doreen N.; Taheri, Diana; Springer, Simeon U.; Cowan, Morgan; Guner, Gunes; Rodriguez, Maria A. Mendoza; Pena, Maria Del Carmen Rodriguez; Wang, Yuxuan; Kinde, Isaac; Ricardo, Bernardo F. P.; Cunha, Isabela; Fujita, Kazutoshi; Kinzler, Kenneth W.; Bivalacqua, Trinity J.; Papadopoulos, Nickolas; Vogelstein, Bert; Netto, George J.; N/A; Baydar, Dilek Ertoy; Faculty Member; School of Medicine; 8025
    Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Although the cadherin 1 (CDH1) gene is commonly mutated in the clinically aggressive plasmacytoid variant of urothelial carcinoma (PUC), little is known about their TERT promoter mutation status. A retrospective search of our archives for PUC and UC with plasmacytoid and/or signet ring cell features (2007-2014) was performed. Ten specimens from 10 patients had archived material available for DNA analysis and were included in the study. lntratumoral areas of nonplasmacytoid histology were also evaluated when present. Samples were analyzed for TERTpromoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform. TERT promoter mutations were detected in specimens with pure and focal plasmacytoid features (6/10). Similar to conventional UC, the predominant mutation identified was g.1295228C>T. In heterogeneous tumors with focal variant histology, concordant mutations were found in plasmacytoid and corresponding conventional, glandular, or sarcomatoid areas. Co-occurring mutations in tumor protein p53 (TP53, 2 cases) and kirsten rat sarcoma (KRAS) viral proto-oncogene (1 case) were also detected. TERT promoter mutations are frequently present in PUC, which provides further evidence that TERT promoter mutations are common events in bladder cancer, regardless of histologic subtype, and supports their inclusion in any liquid biopsy assay for bladder cancer.
  • Placeholder
    PublicationMetadata only
    The impact of visible tumor (PI-RADS >= 3) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: a biopsy core based analysis
    (Cig Media Group, Lp, 2022) Kilic, Mert; Saglican, Yesim; Tugcu, Volkan; Bakir, Baris; N/A; Özkan, Arif; Köseoğlu, Ersin; Balbay, Mevlana Derya; Canda, Abdullah Erdem; Kordan, Yakup; Kiremit, Murat Can; Esen, Tarık; Baydar, Dilek Ertoy; Çil, Barbaros Erhan; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 289255; 350876; 153320; 116202; 157552; 222920; 50536; 8025; 169993
    Deciding on the management of prostate cancer (PCa), especially GG1 PCa, is quite difficult. The most important thing that will help us in making active surveillance or definitive treatment decision is whether the tumor is a clinically significant tumor. To understand this, we discussed in this article that multiparametric MR, PI-RADS scoring and targeted biopsy can be used. Background
  • Placeholder
    PublicationMetadata only
    Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa
    (Wiley, 2020) Taş-Aygar, Gamze; Gönül, Muzeyyen; Özcan, İbrahim; Ayli, Mehmet Deniz; Baydar, Dilek Ertoy; Faculty Member; School of Medicine; 8025
    Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of follicular epithelium; many comorbidities occur that disrupt the quality of life of patients. Amyloidosis is one of them. We present a case with systemic amyloidosis secondary to HS and responding positively to secukinumab therapy. Secukinumab may also be an important option for amyloidosis findings in HS patients.